MedTrace Logo

A Comparative Study of Endoscopic Submucosal Dissection and Photodynamic Therapy for Early Esophageal Cancer

NCT05208775 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2022-01-26

No results posted yet for this study

Summary

The purpose of this study was to compare the efficacy and safety of Photodynamic therapy (PDT) and Endoscopic submucosal (ESD) dissection in the treatment of early esophageal cancer.

Conditions

  • Esophageal Carcinoma in Situ AJCC V7

Interventions

PROCEDURE

PDT

Drug: (Hematoporphyrin sodium injection) Hematoporphyrin sodium injection (xibofen):2mg/kg I.V. Laser irradiation: 48 hours after the patient input the photosensitizer, the laser irradiation time is 900 seconds, and the output power is 200 watts.

PROCEDURE

ESD

The patients received standard endoscopic submucosal dissection after enrollment.

Sponsors & Collaborators

  • The First Affiliated Hospital of Henan University of Science and Technology

    lead OTHER

Principal Investigators

  • Shegan Gao, MD, PhD · The First Affiliated Hospital and College of Henan University of Science and Technology

  • Tanyou Shan, MD, PhD · The First Affiliated Hospital and College of Henan University of Science and Technology

  • Lijuan Wu, MD, PhD · The First Affiliated Hospital and College of Henan University of Science and Technology

  • Caihong Dong, MD，PhD · The First Affiliated Hospital and College of Henan University of Science and Technology

  • Jiachun Sun, MD, PhD · The First Affiliated Hospital and College of Henan University of Science and Technology

  • Wanying Li, MD · The First Affiliated Hospital and College of Henan University of Science and Technology

  • Xiaozhi Yuan, MD, PhD · The First Affiliated Hospital and College of Henan University of Science and Technology

  • Mengxi Zhang, MD · The First Affiliated Hospital and College of Henan University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2022-12-31
Completion
2024-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05208775 on ClinicalTrials.gov